Navigation Links
New company to develop novel gene therapies
Date:2/12/2014

WORCESTER, MA UMass Medical School (UMMS) recognizes the launch today of Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience, to develop life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS).

UMMS researchers Phillip D. Zamore, PhD, co-director of the RNA Therapeutics Institute, and Guangping Gao, PhD, director of the Gene Therapy Center, are two of the scientific founders.

Voyager Therapeutics will focus on an adeno-associated virus (AAV) approach to gene therapy, which has the potential to transform treatment for a wide range of CNS diseases with one-time therapies that may dramatically improve patients' lives. The company is committed to advancing the field of AAV gene therapy by innovating and investing in areas such as vector optimization and engineering, dosing techniques, and process development and production.

Voyager's scientific and clinical founders are leaders in the fields of AAV gene therapy, expressed RNA interference (RNAi) and neuroscience and include:

  • Krystof Bankiewicz, MD, PhD, a translational neurosurgeon and leader in AAV gene therapy who has brought multiple new AAV therapies to the clinic; he is the Kinetics Foundation Chair in Translational Research and a Professor in Residence of Neurological Surgery and Neurology at the University of California, San Francisco (UCSF).

  • Guangping Gao, PhD, a leading AAV researcher who has played a key role in the discovery and characterization of new AAV serotypes; he is director of the UMMS Gene Therapy Center & Vector Core; scientific director of the UMMS-China Program Office; professor of microbiology & physiology systems and the Penelope Booth Rockwell Professor in Biomedical Research.

  • Mark Kay, MD, PhD, a leading researcher in the fields of gene therapy and AAV biology, including the identification of new AAV capsids; he is the head of the Division of Human Gene Therapy and professor in the departments of pediatrics and genetics at Stanford University School of Medicine; he is one of the founders of the American Society of Gene and Cell Therapy and is currently the editor of Human Gene Therapy.

  • Phillip D. Zamore, PhD, a leader and innovator in the understanding of RNAi and development of related therapeutic approaches, including expressed RNAi; he is a Howard Hughes Medical Institute Investigator, the Gretchen Stone Cook Chair of Biomedical Sciences, professor of biochemistry & molecular pharmacology and co-director of the RNA Therapeutics Institute at UMMS.

Voyager is launching with multiple clinical and preclinical product programs for CNS diseases in dire need of effective new therapies, including a Parkinson's disease program in an ongoing Phase 1b study with its collaborators at UCSF, as well as preclinical programs for a monogenic form of amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia.

Depending on the disease, Voyager's gene therapy products will use either gene replacement or gene knockdown techniques. By significantly increasing or decreasing production of relevant proteins at targeted sites within the CNS, the goal is to address the underlying biology of the disease and make a meaningful difference for patients.

"We believe the time is right for gene therapy, and we have assembled the expertise, technology and strategies to translate the promise of AAV gene therapy into breakthrough treatments for patients with these devastating CNS diseases," said Mark Levin, interim chief executive officer of Voyager and partner at Third Rock. "We are extremely pleased to join forces with UMMS, a world leader in AAV gene therapy research and translation."

Voyager has entered into license and other agreements with UMMS, UCSF and Stanford University to access relevant technology and data, including certain rights to intellectual property related to expressed RNAi technology discovered at UMMS, clinical data related to the Parkinson's disease program from UCSF and certain rights to AAV intellectual property developed at Stanford.

In order to accelerate its research and development efforts, Voyager has also entered into a broad strategic collaboration with UMMS.

"A renaissance is underway in the field of gene therapy, as its long-held promise is fulfilled," said Terence R. Flotte, MD, executive deputy chancellor, dean of the school of medicine and the Celia and Isaac Haidak Professor in Medical Education at UMMS. "Voyager is poised to be a key player in bringing the power of this technology to patients suffering from tragic neurologic diseases."

Over the past 10 years, AAV has emerged as a highly promising and attractive approach to gene therapy. In clinical trials, AAV has been shown to be a safe and effective gene therapy delivery vehicle. Advances in AAV vector development and related dosing techniques that enable widespread gene delivery in the brain and spinal cord have made AAV particularly well-suited for the treatment of CNS diseases. In addition, improvements in related production technology and approaches have made AAV production more easily scalable and cost effective to meet commercial requirements.

Voyager's founding management team has deep expertise and a track record of building exceptional life science companies.


'/>"/>

Contact: Lisa Larson
lisa.larson@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Related medicine news :

1. What your company can learn from NASA tragedies
2. New Selection Of Ash Wood Caskets Recently Unveiled By Millionaire Casket Company
3. gMed Celebrates Most Successful Consecutive Quarters in Company History
4. Albert & Company International, Inc. Launches New Website
5. Cooper Consulting Partners Selects Launch Agency to Brand New Company
6. Groundbreaking Anti-Aging Facials from Supreme Skin, An Asheville, NC Company Utilizes Non-Invasive DNA Repair to Infuse Skin with Vibrant Health
7. Women’s Coat For Spring 2014 At Popular Clothing Company Skmen.com
8. Company Releases New CE Course on Current ASAM Criteria for Healthcare Professionals
9. White Label SEO Company, XLocal, Shares Local SEO Strategy Details
10. Northern Virginia Real Estate Company Pasquali Realty Group Suggests These New Year’s Resolutions For Homeowners
11. Conservation Company Adopts a Line of Advanced Zero Energy Exit Signs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life Insurance Company ... life insurance throughout various life stages. , The site launched on April 1, ... and content specific to the times when life insurance matters most. , “Through ...
(Date:5/2/2016)... ... May 02, 2016 , ... The National Resident Matching Program® ... Match® (“the Match”), the system through which U.S. and international medical school students ... positions were placed in the 2016 Match, and 29,572 were filled when the ...
(Date:5/2/2016)... NY (PRWEB) , ... May 02, 2016 , ... Over ... the year’s best in pet gear and toys, leading product review site for Toys, ... Paw of Excellence Awards at their Spring Showcase at the Metropolitan Pavilion in ...
(Date:5/2/2016)... Rhinebeck, NY (PRWEB) , ... May 02, 2016 , ... ... Valley, reopened for its 2016 guest season which runs through October. Omega is offering ... talks . , “There has never been such widespread interest in or ...
(Date:5/2/2016)... ... ... Dr. Rassouli, dentist in Orange County, CA comments on the ... was published in the “Journal of the American Geriatrics Society,” more than a third ... Alzheimer’s disease. The study found that dental problems may increase the risk of heart ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
Breaking Medicine Technology: